EP2762151A1 - Exogenes opioidpeptid-abbauendes enzym - Google Patents

Exogenes opioidpeptid-abbauendes enzym Download PDF

Info

Publication number
EP2762151A1
EP2762151A1 EP12837135.8A EP12837135A EP2762151A1 EP 2762151 A1 EP2762151 A1 EP 2762151A1 EP 12837135 A EP12837135 A EP 12837135A EP 2762151 A1 EP2762151 A1 EP 2762151A1
Authority
EP
European Patent Office
Prior art keywords
enzyme preparation
opioid peptide
peptide
enzyme
exogenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12837135.8A
Other languages
English (en)
French (fr)
Other versions
EP2762151A4 (de
Inventor
Hirotaka Matsubara
Hiroki Ido
Satoshi Koikeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amano Enzyme Inc
Original Assignee
Amano Enzyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amano Enzyme Inc filed Critical Amano Enzyme Inc
Publication of EP2762151A1 publication Critical patent/EP2762151A1/de
Publication of EP2762151A4 publication Critical patent/EP2762151A4/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/195—Proteins from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/62—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from Aspergillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to an enzyme preparation and the uses thereof. More specifically, the present invention relates to an enzyme preparation showing a degradation activity for exogenous opioid peptides, and pharmaceutical compositions and others.
  • This application claims the benefit of priority from prior Japanese Patent Application No. 2011-215525, filed September 29, 2011 , the entire contents of which are incorporated herein by reference.
  • casomorphin milk-derived
  • gliadorphin wheat-derived
  • these peptides cannot be digested (degraded) in the child body with childhood autism. Therefore, gluten-free and casein-free diet may be put on the patients with childhood autism.
  • Patent Documents 1 to 6 There are attempts to relieve the autism symptoms by the enzyme compositions containing a casomorphin/gluteomorphine inhibitor.
  • the present invention is intended to provide a means for efficiently degrading an exogenous opioid peptide, thereby contributing the establishment of the therapy for diseases and clinical states related to an exogenous opioid peptide.
  • the present inventors studied the degradation activity of various enzyme preparations for gliadorphin and casomorphin. As a result of dedicated research, they found the enzyme preparations showing strong degradation activity and promoting efficient degradation of gliadorphin and casomorphin. In addition, it was also revealed that the combination of a plurality of enzyme preparations, which may be further combined with a proteolytic enzyme, achieves synergistic effect, and allows highly efficient degradation of gliadorphin and casomorphin. Therefore, the study by the present inventors has found the enzyme preparations which are expected to be effective for the treatment of autism, and has revealed more effective usage (more specifically, specific embodiments of combinations). The following aspects of the present invention are based on these findings.
  • a first aspect of the present invention relates to a novel enzyme preparation.
  • the enzyme preparation of the present invention contains one or more components selected from the group consisting of an enzyme preparation from Penicillium citrinum, an enzyme preparation Aspergillus oryzae, and an enzyme preparation Aspergillus melleus.
  • the enzyme preparation of the present invention shows degradation activity owing to its components for wheat gluten-derived and casein-derived opioid peptides, which are exogenous opioid peptides.
  • the term "enzyme preparation” means a composition obtained by processing a material containing the target enzyme (for example, a culture solution of a microorganism), and contains one or more enzymes.
  • processing herein usually means purification, but the method for the purification is not limited.
  • opioid peptide means a peptide showing a specific action to an opioid receptor, or its related peptide and may be endogenous or exogenous. Endogenous opioid peptides are broadly divided into endorphins, enkephalins, and dynorphins, depending on the type of the receptor on which they act. The exogenous opioid peptide is also referred to as "exorphin". Typical examples of the exogenous opioid peptide is food-derived opioid peptides.
  • ⁇ -casomorphin and ⁇ -casein-exorphin derived from casein examples include ⁇ -casomorphin and ⁇ -casein-exorphin derived from casein, and gliadorphin (gluteomorphine) derived from wheat gluten ( Henschen A. et al., Hoppe-Seyler's Z. Physiol. Chem.,360,1217 (1979 ).; Lottspeich,F. et al., Hoppe Seyler's Z. Physiol. Chem. 361, 1835-1839 (1980 ).; Loukas S. et al., Biochemistry. 13, 22 (19): 4567-73 (1983 ).; Zioudrou C et al., J Biol Chem.
  • Gliadorphin is also contained in rye, barley, and oat.
  • the enzyme preparation of the present invention efficiently degrades wheat gluten-derived and casein-derived opioid peptides.
  • the enzyme preparation of the present invention cuts the wheat gluten-derived and casein-derived opioid peptides at one or more positions.
  • the enzyme preparation of the present invention showed a strong degradation activity for the amino acid sequence YPQPQPF (Tyr-Pro-Gln-Pro-Gly-Pro-Phe) (SEQ ID NO: 2) which is characteristic to gliadorphin 7, and the amino acid sequence YPFPGPI (Tyr-Pro-Phe-Pro-Gly-Pro-Ile) (SEQ ID NO: 3) which is characteristic to ⁇ -casomorphin 7.
  • the enzyme preparation of the present invention is further characterized in that it shows degradation activity for the amino acid sequence YPQPQPF (SEQ ID NO: 2), and/or shows strong degradation activity for the amino acid sequence YPFPGPI (SEQ ID NO: 3).
  • Patent Documents 1 to 7 mention the use of the gliadorphin (gluteomorphine) inhibitor, but the sequence of gliadorphin therein is GYYPT (Gly-Tyr-Tyr-Pro-Thr) (SEQ ID NO: 4), GFFP (Gly-Phe-Phe-Pro) (SEQ ID NO: 5), FGGYL (Phe-Gly-Gly-Tyr-Leu) (SEQ ID NO: 6), or FGGY (Phe-Gly-Gly-Tyr) (SEQ ID NO: 7), and is completely different from the sequence of gliadorphin in the present invention (SEQ ID NO: 2). At least at this point, the present invention should be distinguished from the arts disclosed in Patent Documents 1 to 7.
  • each of the enzyme preparations from Penicillium citrinum, Aspergillus oryzae, and Aspergillus melleus showed strong degradation activity for gliadorphin and casomorphin.
  • the enzyme preparation from Penicillium citrinum showed the strongest degradation activity.
  • Yet another embodiment contains the enzyme preparation from Aspergillus melleus as a third component.
  • the combination of the enzyme preparations from Penicillium citrinum, Aspergillus oryzae, and Aspergillus melleus is expected to achieve additive or synergistic effect, as shown in the examples.
  • Gliadorphin and casomorphin have a homologous amino acid sequence motif "Tyr-Pro-X-Pro-X-Pro-X (SEQ ID NO: 8)", and are praline-rich resistant peptides.
  • the enzyme preparation from Penicillium citrinum exhibits a high degradation activity for gliadorphin and casomorphin as shown in the examples. In other words, it exhibits a degradation activity which can be detected by the FRETS method shown in the below-described examples using the FRETS substrate containing the both peptide sequences (degradability evaluation by the FRETS substrate).
  • the enzymatic activity liberating 1 ⁇ M of Nma per minute upon reaction at 37°C is set as 1 unit (u).
  • the degradation activity of the enzyme preparation from Penicillium citrinum was evaluated by the above-described method, and an excellent degradation activity for gliadorphin (SEQ ID NO: 2) (about 6,300 u/g) and casomorphin (SEQ ID NO: 3) (about 5,900 u/g) was detected.
  • the enzyme preparation from Aspergillus oryzae also exhibited a high degradation activity for gliadorphin (SEQ ID NO: 2) (about 6,000 u/g) and casomorphin (SEQ ID NO: 3) (about 2,200 u/g).
  • the enzyme preparation from Aspergillus melleus also exhibited a strong degradation activity for gliadorphin (SEQ ID NO: 2) (about 14,000 u/g).
  • the enzyme preparation from Penicillium citrinum can be prepared by an ordinary procedure. For example, after filtrating a culture solution of Penicillium citrinum, the filtrate is concentrated by, for example, ultrafiltration. As necessary, purification by ammonium sulfate precipitation, dialysis, desalt, or any chromatography is carried out. Furthermore, for example, spray drying or ethanol precipitation may be used to prepare the final product.
  • the enzyme preparation from Penicillium citrinum may be used at a predetermined concentration, and may be diluted or concentrated before use.
  • the enzyme preparation from Penicillium citrinum may be replaced with an enzyme preparation derived from a plant, animal, or microorganism, as long as it exhibits a degradation activity equivalent to that of the enzyme preparation from Penicillium citrinum.
  • an enzyme preparation derived from other fungi for example, Aspergillus niger
  • bacterium Actinomyces bacterium such as Streptomyces aureus
  • the enzyme preparation from Aspergillus oryzae may be prepared by an ordinary procedure. For example, a culture solution of Aspergillus oryzae is filtered, and then the filtrate is concentrated by, for example, ultrafiltration. As necessary, purification is carried out by ammonium sulfate precipitation, dialysis, desalting, or any chromatography. Furthermore, for example, spray-dry method or ethanol precipitation may be used to obtain the final product.
  • the enzyme preparation from Aspergillus oryzae may be used at a predetermined concentration, and may be diluted or concentrated before use.
  • the enzyme preparation from Aspergillus melleus may be prepared by an ordinary procedure. For example, a culture solution of Aspergillus melleus is filtered, and then the filtrate is concentrated by, for example, ultrafiltration. As necessary, purification is carried out by ammonium sulfate precipitation, dialysis, desalting, or any chromatography. Furthermore, for example, spray drying or ethanol precipitation may be used to obtain the final product.
  • the enzyme preparation from Aspergillus melleus may be used at a predetermined concentration, and may be diluted or concentrated before use.
  • the enzyme preparation from Aspergillus oryzae contains at least Oryzin, neutral protease I (NPI), and neutral protease II (NPII).
  • the enzyme preparation from Aspergillus melleus contains a semi-alkaline protease.
  • semi-alkaline protease means an enzyme hydrolyzing a protein and its degradation products (polypeptide, peptide), and exhibits an activity in the pH range of 6.0 to 11.
  • a specific protease component contained in the enzyme preparation from Aspergillus oryzae may be used.
  • aorsin is a serine proteinase having trypsin-like specificity in the acidic pH range, and can be purified from the enzyme preparation from Aspergillus oryzae.
  • the details about aorsin A and aorsin B are described in Japanese Patent No. 4401555 and Japanese Unexamined Patent Application Publication No. 2009-232835 . The entire contents of these patent documents are incorporated herein by reference.
  • Aorsin efficiently hydrolyzes a gluten-derived peptide in the acidic pH range.
  • nucleotide sequence and amino acid sequence of aorsin are disclosed in the literature by Lee et al. (Biockem. J. 371 (PT 2), 541-548 (2003)).
  • the nucleotide sequence of aorsin A is registered in GenBank under accession number AB084899.1.
  • the corresponding amino acid sequence is registered under accession number BAB97387.
  • aorsin B the nucleotide sequence and amino acid sequence are registered in GenBank under accession numbers XM001820783.1 and XP_001820835.1, respectively.
  • An enzyme containing the amino acid sequence of aorsin or an enzyme containing the amino acid sequence having an identity of 70% or more to the amino acid sequence of aorsin may be used.
  • the identity is preferably at least 80%, more preferably at least 90%, and even more preferably at least 99%.
  • the enzyme having an amino acid sequence equivalent to the amino acid sequence of aorsin may be used. These two amino acid sequences are regarded as equivalent when the identity is at least 80%, preferably at least 90%, and even more preferably at least 99%, and the functions are also equivalent.
  • the equivalent sequences can be identified by, for example, the GAP program of the GCG software package, or the sequence comparison algorithm such as BLAST or FASTA.
  • protease and peptidase for example, a semi-alkaline protease, a protease (for example, papain, chymopapain, trypsin, or chymotrypsin), or carboxypeptidase may be used as an additional component (optional component).
  • a semi-alkaline protease for example, papain, chymopapain, trypsin, or chymotrypsin
  • carboxypeptidase may be used as an additional component (optional component).
  • the enzyme preparation of the present embodiment achieves additive or synergistic effect, and allows more efficient degradation of exogenous opioid peptides.
  • the protease may be a commercial product (for example, Papain W-40).
  • the commercial product is used at the original concentration or after diluted or concentrated.
  • the enzyme may be not a commercial product but a freshly purified protease.
  • the purification method may be, for example, salting out, filtration, ultrafiltration, centrifugation, or any chromatography (for example, ion exchange chromatography, or affinity chromatography).
  • an activated protease for example, activated papain
  • papain can be activated by a reducing agent.
  • the reducing agent used for this activation include glutathione, dithiothreitol (DTT), L-cysteine, and N-acetyl L-cysteine.
  • a protease or peptidase which does not have degradation activity for exomorphin peptide by itself may be used. As shown in the examples, papain did not exhibit direct degradability for exomorphine peptide, but contributes to the improvement in degradability of the gliadorphin-containing peptide.
  • An endopeptidase and an exopeptidase may be used for degradation.
  • the exopeptidase include carboxypeptidase Y (CPY).
  • CPY is also referred to as protease C or yscY.
  • CPY is an exopeptidase having a wide range of specificity, and liberates amino acid from the carboxy terminal of a protein or peptide.
  • CPY belongs to the serine carboxypeptidase family, and shows a high level of sequence conservation. The activating region of CPY is surrounded by serine and a histidine residue which are essential for activation.
  • CPY derived from a yeast or fungi for example, Saccharomyces, Schizosaccharomyces, Aspergillus, Candida, Pichia
  • yeast or fungi for example, Saccharomyces, Schizosaccharomyces, Aspergillus, Candida, Pichia
  • CPY having an amino acid sequence identity of at least 70%, preferably at least 80%, more preferably at least 90%, and even more preferably 100% with the CPY from Saccharomyces cerevisiae, Aspergillus niger, Schizosaccharomyces pombe, or Aspergillus fumigatus may be used.
  • the components of the enzyme preparation of the present invention may be prepared from a natural microorganism which produces these components. Alternatively, these components may be prepared from a transgenic microorganism (so-called mutant).
  • the components of the enzyme preparation of the present invention may be prepared from a natural plant which produces these components in the form of an enzyme having a degradation activity.
  • these components may be prepared from a transgenic plant (so-called mutant).
  • the enzyme preparation of the present invention may further contain, in addition to the active ingredient, for example, an excipient, a buffering agent, a suspending agent, a stabilizer, a preservative, an antiseptic, and a normal saline solution.
  • excipient include lactose, sorbitol, D-mannitol, and white sugar.
  • buffering agent include phosphates, citrates, and acetates.
  • the stabilizer include propylene glycol and ascorbic acid.
  • the preservative include phenol, benzalkonium chloride, benzyl alcohol, chlorobutanol, and methylparaben.
  • the antiseptic include benzalkonium chloride, paraoxybenzoic acid, and chlorobutanol.
  • the enzyme preparation of the present invention exhibits degradation action on exogenous opioid peptides, and may be applied to a disease or clinical state related to an exogenous opioid peptide. Accordingly, another aspect of the present invention provides a pharmaceutical or food composition including the enzyme preparation of the present invention for a disease or clinical state related to an exogenous opioid peptide.
  • exogenous opioid peptide-related disease the "disease or clinical state related to an exogenous opioid peptide" is referred to as “exogenous opioid peptide-related disease” for convenience.
  • Related to an exogenous opioid peptide means that the exogenous opioid peptide is at least a cause of the expression (more specifically development or onset) or progress of the disease or clinical state.
  • the therapeutic effects include the relief (alleviation) of the symptoms characteristic to or associated with the exogenous opioid peptide-related disease, and prevention or delay of the symptoms.
  • the latter can be regarded as one of the prophylactic effects in the prevention of progression of the disease. In this manner, the therapeutic and prophylactic effects are partially overlapped. Therefore, it is difficult and not beneficial to clearly discriminate them.
  • a typical prophylactic effect is the prevention or delay of the expression (development) of symptoms characteristic to exogenous opioid peptide-related diseases. As long as it shows any therapeutic effect and/or prophylactic effect for exogenous opioid peptide-related diseases, it is classified as a remedy for exogenous opioid peptide-related diseases.
  • Casomorphin and gliadorphin which are exogenous opioid peptides, are suggested to be related to autism which is a typical pervasive developmental disorder, and mental disorders (mental sickness) such as integration disorder syndrome, and depression (especially postpartum depression)
  • autism is a typical pervasive developmental disorder, and mental disorders (mental sickness) such as integration disorder syndrome, and depression (especially postpartum depression)
  • mental disorders such as integration disorder syndrome, and depression (especially postpartum depression)
  • the "exogenous opioid peptide-related disease" to which the composition of the present invention may be used is, for example, pervasive developmental disorder, integration disorder syndrome, or depression.
  • the pervasive developmental disorder herein includes autism, Asperger's syndrome, Rett's disorder, childhood disintegrative disorder, and pervasive developmental disorder - not otherwise specified.
  • the composition of the present invention is provided for the treatment of prevention of autism, integration disorder syndrome, or depression (postpartum depression). More preferably, the composition of the present invention is provided for the treatment or prevention of autism.
  • the formulation of the pharmaceutical composition of the present invention may use a common procedure.
  • other components which are acceptable for formulation for example, a carrier, an excipient, a disintegrating agent, a buffering agent, an emulsifying agent, a suspending agent, a soothing agent, a stabilizer, a preservative, an antiseptic, and a normal saline solution
  • examples of the excipient include lactose, starch, sorbitol, D-mannitol, and white sugar.
  • the disintegrating agent include starch, carboxymethyl cellulose, and calcium carbonate.
  • the buffering agent include phosphates, citrates, and acetates.
  • Examples of the emulsifying agent include gum arabic, sodium alginate, and tragacanth.
  • the suspending agent include glycerol monostearate, monostearic acid aluminum, methyl cellulose, carboxymethyl cellulose, hydroxymethyl cellulose, and sodium lauryl sulfate.
  • Examples of the soothing agent include benzyl alcohol, chlorobutanol, and sorbitol.
  • Examples of the stabilizer include propylene glycol, and ascorbic acid.
  • Examples of the preservative include phenol, benzalkonium chloride, benzyl alcohol, chlorobutanol, and methylparaben.
  • Examples of the antiseptic include benzalkonium chloride, paraoxybenzoic acid, and chlorobutanol.
  • the form of formulation is not particularly limited, and the medicine of the present invention may be provided in the form of, for example, pellets, a powder, fine pellets, granules, capsules, a syrup, or an injection.
  • the pharmaceutical composition of the present invention contains an active ingredient in an amount enough for achieving the expected therapeutic effect (includes prophylactic effect), more specifically, the therapeutic effect for exogenous opioid peptide-related diseases (more specifically, therapeutically effective amount).
  • the amount of the active ingredient in the pharmaceutical composition of the present invention generally depends on the dosage form, and is, for example, about 0.1% to 95% by weight, thereby achieving the intended dose.
  • the pharmaceutical composition of the present invention is administered to the patient (or potential patient) orally or parenterally according to the dosage form.
  • parenteral administration herein is not particularly limited, and examples include intravenous, intramuscular, intraarterial, intraspinal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, percutaneous transluminal, hypodermic, subepidermal, intraarticular, intraarticular, subarachnoid, intraspinal, and intrasternal infusion and injection.
  • the dose of the pharmaceutical composition of the present invention is established so as to achieve the expected therapeutic effect.
  • the symptoms, the age, sex, and body weight of the patient, and other factors are taken into consideration.
  • the dose for an adult may be established in such a manner that the amount of the active ingredient is about 10 mg to 2,000 mg, preferably about 50 mg to 1,000 mg, and more preferably about 100 mg to 700 mg a day.
  • the administration schedule may be, for example, once to several times a day, once every two days, or once every three days.
  • the disease state of the patient, and the expected duration of the effect of the active ingredient may be taken into consideration.
  • one embodiment of the present invention is a food composition containing the enzyme preparation of the present invention.
  • the "food composition” of the present invention include general foods (for example, grains, vegetables, meat, various processed foods, confectioneries, milk, refreshing beverages, and alcohol beverages), dietary supplements (supplements and nutrition drinks), and food additives.
  • the form may be, for example, a powder, granules, tablets, a paste, or a liquid.
  • the food composition of the present invention preferably contains an active ingredient in an amount enough for achieving therapeutic or prophylactic effect.
  • the loading may be established in consideration of, for example, the disease state, health condition, age, sex, and body weight of the subject.
  • a 33-mer peptide (LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF: SEQ ID NO: 1), which is a resistant peptide containing gliadorphin, is the amino acid sequence of No. 56-88 of ⁇ 2 gliadin composing gluten.
  • a blank prepared by adding miliQ (registered trademark) water in place of an enzyme, and a sample blank prepared by adding an enzyme solution which had been boiled for 10 minutes for heat inactivation were prepared.
  • 33-mer peptide solution (1 mg/mL miliQ (registered trademark)) 10 ⁇ l
  • Enzyme solution (containing 0.2 mg/mL of 20 mM sodium acetate buffer (pH 4.5) and 0.15 mg of an enzyme; when a four-mixed enzyme preparation is used, containing 0.015 mg of ACEP, 0.015 mg of papain, 0.015 mg of AMEP, and 0.015 mg ofPCEP) 10 ⁇ l 150 mM sodium acetate buffer (pH 4.5) 10 ⁇ l (2) Allowed to react at 37°C for 1 hour.
  • Fig. 1 The determination results are shown in Fig. 1 .
  • the ordinate of the graph in Fig. 1 is the residual rate of gliadorphin. It is shown that gliadorphin was almost completely degraded by the four-mixed enzyme preparation.
  • each of AOEP, AMEP, and PCEP exhibited a high degradation activity by itself.
  • the casomorphin degradability of the enzymes and four-mixed enzyme preparation was studied in the same manner as in 1.
  • the substrate was a resistant peptide containing casomorphin (YPFPGPI: SEQ ID NO: 3).
  • the determination of casomorphin used "Beta Casomorphin, EIA Kit Cat. No. S-1334" manufactured by BACHEM.
  • the determination results are shown in Fig. 2 .
  • the ordinate of the graph in Fig. 2 is the residual rate of casomorphin. It is shown that casomorphin was almost completely degraded by the four-mixed enzyme preparation.
  • each of AOEP, AMEP, and PCEP showed a degradation activity by itself. In particular, the degradation activity of PCEP was high.
  • the peptide sequence (YPQPQPF: SEQ ID NO: 2) of gliadorphin was completely synthesized, and used as the substrate.
  • the above-described four-mixed enzyme preparation and each of the four enzyme/enzyme preparation composing it were individually allowed to act on gliadorphin, and the degradation product was analyzed by LC-MS.
  • the sample reacted without enzyme addition was used as the control.
  • the degradation product obtained by the reaction of pepsin was also analyzed. As a result of this, the degradation fragment pattern shown in Fig. 3 was obtained. It is shown that each of PCEP, AOEP, and AMEP degraded gliadorphin by itself.
  • the peptide sequence (YPFPGPI: SEQ ID NO: 3) of casomorphin was completely synthesized, and used as the substrate.
  • the above-described four-mixed enzyme preparation and each of the four enzyme/enzyme preparation composing it were individually allowed to act on casomorphin, and the degradation product was analyzed by LC-MS.
  • the sample reacted without enzyme addition was used as the control.
  • the degradation product obtained by the reaction of pepsin was also analyzed.
  • the degradation fragment pattern shown in Fig. 4 was obtained. It is shown that each of PCEP, AOEP, and AMEP degraded casomorphin by itself. However, undegraded 7-mer was detected when the enzyme/enzyme preparation were used singly, but no undegraded 7-mer was detected when the four-mixed enzyme preparation was used. Therefore, the four-mixed enzyme preparation showed synergistic effect.
  • FRETS Fluorescence Resonance Energy Transfer Substrate
  • FRETS Fluorescence Resonance Energy Transfer Substrate
  • gliadorphin The evaluation results are shown in Fig. 5 .
  • the result of the evaluation using the FRETS substrate containing the amino acid sequence (YPQPQPF: SEQ ID NO: 2) of gliadorphin is also shown.
  • AOEP and PCEP showed a strong casomorphin degradation activity.
  • the degradation activity of PCEP was particularly strong.
  • For gliadorphin, AOEP, AMEP, and PCEP showed a strong degradation activity.
  • the degradation activity of AMEP was markedly strong.
  • PCEP Penicillium citrinum
  • Penicillium citrinum stored in a public culture collection (NBRC 6026, JCM 22500, JCM 5591 (NBRC 6026), IFO 6225, JCM 22508, JCM 22511, JCM 22517, and JCM 22519) were inoculated from ampoules on Malt extract Agar slant culture media. They were cultured in a thermostat bath at 25°C for 3 to 5 days. The colonies were aseptically cut into a 5 mm square using a platinum wire loop, and inoculated in 50 mL of Malt extract culture medium in a 300-mL conical flask.
  • the colonies were cultured on a rotary (200 rpm, 25°C) for 12 days, and the degradation activity of the FRETS substrates (the FRETS substrate containing the amino acid sequence of gliadorphin or casomorphin) in the culture supernatant was measured.
  • the measurement method followed the method of 5.
  • the mixture was warmed until the agar dissolved, and dispensed in 7 mL portions into a 18 mm diameter test tube. After pasteurization at 121°C for 20 minutes, the test tube was tilted and allowed to stand overnight, whereby the medium was solidified and used as a slant culture medium.
  • the mixture was dispensed in 50 mL portions into a 300-mL conical flask. After pasteurization at 121°C for 20 minutes, the medium was cooled to room temperature, and used for culture.
  • the physiological activity of the gliadorphin degradation product and casomorphin degradation product was evaluated by Mu opioid receptor ligand binding assay kit (manufactured by Cisbio). This kit uses the cells which expressed the human Mu opioid receptor to determine the opioid receptor-bound molecules in the sample by the time resolved fluorescence (TR-FRET) method.
  • the buffer was sodium acetate (pH 4.5) with the final concentration of 50 mM.
  • the opioid peptides were gliadorphin, casomorphin, and a wheat-derived 33-mer peptide containing the opioid peptide sequence at the C-terminal side were individually added to the reaction system at the final concentration of 0.33 mg/ mL.
  • PCEP Penicillium citrinum
  • AOEP Aspergillus oryzae
  • AMEP Aspergillus melleus
  • papain was individually added at the final concentration of 50 mg/L.
  • test sections prepared using the above-described peptides and enzyme at a 10-fold concentration (10-fold concentrated sample) were also provided. After reaction for 120 minutes at 37°C, the enzyme was deactivated by boiling for 15 minutes, the solid content was removed from the supernatant by centrifugation at 15,000 rpm for 10 minutes, and the supernatant was used as the sample for evaluation using the kit.
  • the value of TR665 nm/TR620 nm was acquired and calculated. The results of each sample were shown in Figs. 7 to 9 .
  • a terbium-labeled opioid receptor binding ligand and an opioid receptor-bound molecule in the sample are competitively bound to the receptor, and the fluorescence is measured. Therefore, the higher the value of TR665 nm/TR620 nm is, the less opioid receptor-bound molecules are present in the sample, and the higher the value is, the more opioid receptor-bound molecule are present in the sample.
  • the TR665 nm/TR620 nm value was higher for those with enzyme addition (indicated with “+” in the figures) than those without enzyme addition (indicated with "-” in the figures). This result means that the number of the opioid receptor-bound molecules decreased by the enzyme addition.
  • the enzyme preparation of the present invention exhibits a degradation activity for exogenous opioid peptides, and is expected to be used for the treatment of exogenous opioid peptide-related diseases such as autism.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP12837135.8A 2011-09-29 2012-08-31 Exogenes opioidpeptid-abbauendes enzym Withdrawn EP2762151A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011215525 2011-09-29
PCT/JP2012/072117 WO2013047082A1 (ja) 2011-09-29 2012-08-31 外因性オピオイドペプチド分解酵素剤

Publications (2)

Publication Number Publication Date
EP2762151A1 true EP2762151A1 (de) 2014-08-06
EP2762151A4 EP2762151A4 (de) 2015-06-03

Family

ID=47995130

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12837135.8A Withdrawn EP2762151A4 (de) 2011-09-29 2012-08-31 Exogenes opioidpeptid-abbauendes enzym

Country Status (4)

Country Link
US (1) US20140219982A1 (de)
EP (1) EP2762151A4 (de)
JP (1) JPWO2013047082A1 (de)
WO (1) WO2013047082A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112056453A (zh) * 2020-08-31 2020-12-11 华南理工大学 一种富含芳香族氨基酸的改善睡眠酶解物及其制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160135819A1 (en) * 2014-11-16 2016-05-19 Spinesmith Partners, L.P. System and method of treatment of bone lesions
AU2018242882B2 (en) 2017-03-28 2021-08-12 Morinaga Milk Industry Co., Ltd. Novel Bifidobacterium genus bacterium
EP3603655A4 (de) 2017-03-28 2021-01-06 Morinaga Milk Industry Co., Ltd. Zusammensetzung zum abbau von opioidpeptiden

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273683A1 (en) * 1998-06-15 1999-12-15 Ortho-Clinical Diagnostics, Inc. Diagnostic markers for human disorders
US6251391B1 (en) 1999-10-01 2001-06-26 Klaire Laboratories, Inc. Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons
US6447772B1 (en) 1999-10-01 2002-09-10 Klaire Laboratories, Inc. Compositions and methods relating to reduction of symptoms of autism
JP4401555B2 (ja) 2000-10-27 2010-01-20 天野エンザイム株式会社 新規なキモトリプシン様プロテア−ゼ及びその製造法並びに新規なキモトリプシン様プロテアーゼを作用させるタンパク質分解物含有物の製造法。
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
DK1663298T3 (da) * 2003-09-23 2019-10-14 Dsm Ip Assets Bv Anvendelse af prolinspecifikke endoproteaser til hydrolyse af peptider og proteiner
JP4619730B2 (ja) * 2004-09-07 2011-01-26 イーエヌ大塚製薬株式会社 風味に優れたアミノ酸・ペプチド混合物及びその製造方法
US20070092501A1 (en) 2005-04-26 2007-04-26 Prothera, Inc. Compositions and methods relating to reduction of symptoms of autism
EP2136833B1 (de) * 2007-03-16 2019-05-01 The Board of Trustees of the Leland Stanford Junior University Kombinationsenzymtherapie zum aufschluss von gluten in der nahrung
JP5329923B2 (ja) 2008-03-04 2013-10-30 天野エンザイム株式会社 新規プロテアーゼ及びその製造法
US20110200574A1 (en) * 2010-02-02 2011-08-18 Jolly James F Use of proteases for gluten intolerance

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112056453A (zh) * 2020-08-31 2020-12-11 华南理工大学 一种富含芳香族氨基酸的改善睡眠酶解物及其制备方法
CN112056453B (zh) * 2020-08-31 2022-05-24 华南理工大学 一种富含芳香族氨基酸的改善睡眠酶解物及其制备方法

Also Published As

Publication number Publication date
US20140219982A1 (en) 2014-08-07
EP2762151A4 (de) 2015-06-03
WO2013047082A1 (ja) 2013-04-04
JPWO2013047082A1 (ja) 2015-03-26

Similar Documents

Publication Publication Date Title
RU2370279C2 (ru) Применение пролинспецифичных эндопротеаз для гидролиза пептидов и белков
AU2010334383B2 (en) Synergic action of a prolyl protease and tripeptidyl proteases
JP4839215B2 (ja) 新規真菌タンパク質および同タンパク質をコードする核酸
EP1568377A1 (de) Cysteinprotease-hemmer
KR101244995B1 (ko) 글리코마크로펩타이드로부터의 혈압 강하 펩타이드
US20120189611A1 (en) Dipeptidyl peptidase-4 inhibitor
EP2762151A1 (de) Exogenes opioidpeptid-abbauendes enzym
US20100286034A1 (en) Uses for aqueous streams containing proteins
KR101418968B1 (ko) ＣＨＰ(ｃｙｃｌｏ(Ｈｉｓ-Ｐｒｏ))를 고농도로 함유한 대두 가수분해물을 포함하는 혈당 조절용 조성물
KR101230650B1 (ko) 홍어 껍질 유래의 알츠하이머 질병의 억제 또는 예방을 위한 조성물
KR102283751B1 (ko) 돈태반 효소 가수분해물과 산 분해물의 혼합물을 포함하는 간 보호용 조성물
JP2005139084A (ja) システインプロテアーゼ阻害剤
WO2016120764A1 (en) Aspergillus oryzae prolyl endopeptidases and use thereof in degradation of polypeptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140429

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150504

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/58 20060101ALI20150427BHEP

Ipc: A23L 1/305 20060101ALI20150427BHEP

Ipc: A61K 35/74 20150101ALI20150427BHEP

Ipc: A61K 38/46 20060101AFI20150427BHEP

Ipc: C12N 9/48 20060101ALI20150427BHEP

Ipc: A61P 39/02 20060101ALI20150427BHEP

Ipc: A61P 25/18 20060101ALI20150427BHEP

17Q First examination report despatched

Effective date: 20160504

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160915